Development of High Throughput Quantitative PCR Assays for RSV

目前，没有针对呼吸道合胞病毒（RSV）的疫苗，治疗选择有限。在RSV的标准化和通量潜力方面，中和测定的改进将促进新型疫苗和治疗剂的开发。该合同支持开发高通量定量PCR检测试剂盒，以检测人呼吸道合胞病毒（亚型A和B）的中和抗体。

Currently, there are no vaccines available for Respiratory Syncytial Virus (RSV), and treatment options are limited. Improvements in neutralization assays, in terms of standardization and throughput potential, for RSV would facilitate the development of novel vaccines and therapeutics. This contract supports the development of high throughput quantitative PCR assays to detect neutralizing antibody to human respiratory syncytial viruses (subtypes A and B).